首页>
外国专利>
Biomarker composition for predicting drug responsiveness to platinum-based anti-cancer agents in triple negative breast cancer comprising miR-320c
Biomarker composition for predicting drug responsiveness to platinum-based anti-cancer agents in triple negative breast cancer comprising miR-320c
The present invention relates to a biomarker composition for predicting drug responsiveness of patients with triple negative breast cancer to a platinum-based anticancer drug containing miR-320c as an active ingredient. We confirmed that CHEK1 expression was directly regulated by miR-320c, which was down-regulated in most TNBC cell lines. Through further studies, the present inventors have shown that the ectopic restoration of miR-320c in oxaliplatin-treated TNBC cells is through negative regulation of CHEK1, inhibiting DNA damage response, DNA repair, and improving genomic instability, and It has been found to activate death. In addition, the combination of miR-320c analogue and oxaliplatin effectively inhibited tumor progression. The above results indicate that miR-320c plays an important role in the reactivity of TNBC cells to oxaliplatin by regulating CHEK1 expression, which is a therapeutic target for increasing chemotherapy responsiveness, which will be usefully utilized in triple-negative breast cancer treatment strategies. It is expected to be able to.
展开▼
